By Toni Clarke

(Reuters) - The aggregate financial performance of biotechnology companies in four of the world's major markets -- the United States, Europe, Canada and Australia -- improved in 2011, but funding for small companies is increasingly scarce, raising questions as to whether that growth is sustainable long term, according to a new report.